HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas.

Abstract
Most breast carcinomas that are estrogen receptor (ER) and progesterone receptor (PR) positive respond initially to an endocrine therapy, but over time, they develop resistance (acquired hormone resistance). Others, however, fail to respond from the beginning (constitutive resistance). Overcoming hormone resistance is one of the major desirable aims in breast cancer treatment. Using the medroxyprogesterone acetate (MPA)-induced breast cancer mouse model, we have previously demonstrated that antiprogestin-responsive tumors show a higher expression level of PR isoform A (PRA) than PR isoform B (PRB), while tumors with constitutive or acquired resistance show a higher expression level of PRB. The aim of this study was to investigate whether PRA silencing in resistant tumors was due to PRA methylation. The CpG islands located in the PRA promoter and the first exon were studied by methylation-specific PCR (MSP) in six different tumors: two antiprogestin-responsive, two constitutive-resistant, and two with acquired resistance. Only in constitutive-resistant tumors, PRA expression was silenced by DNA methylation. Next, we evaluated the effect of a demethylating agent, 5-aza-2'-deoxycytidine, on PRA expression and antiprogestin responsiveness. In constitutive-resistant tumors, 5-aza-2'-deoxycytidine treatment in vitro and in vivo restored PRA expression and antiprogestin RU-486 responsiveness. Furthermore, high levels of DNA methyltransferase (Dnmts) 1 and 3b were detected in these tumors. In conclusion, our results suggest that methyltransferase inhibitors in combination with antiprogestins may be effective in the treatment of constitutive-resistant carcinomas with a high DNA methyltransferase level.
AuthorsVictoria Wargon, Sandra V Fernandez, Mercedes Goin, Sebastián Giulianelli, Jose Russo, Claudia Lanari
JournalBreast cancer research and treatment (Breast Cancer Res Treat) Vol. 126 Issue 2 Pg. 319-32 (Apr 2011) ISSN: 1573-7217 [Electronic] Netherlands
PMID20440553 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Hormone Antagonists
  • Receptors, Glucocorticoid
  • Receptors, Progesterone
  • progesterone receptor A
  • progesterone receptor B
  • Mifepristone
  • Decitabine
  • DNA Modification Methylases
  • Azacitidine
Topics
  • Animals
  • Apoptosis (drug effects)
  • Azacitidine (analogs & derivatives, pharmacology)
  • Cell Culture Techniques
  • Cell Line, Tumor
  • Coculture Techniques
  • DNA Methylation (drug effects)
  • DNA Modification Methylases (antagonists & inhibitors)
  • Decitabine
  • Drug Resistance, Neoplasm
  • Female
  • Gene Expression Regulation, Neoplastic
  • Gene Silencing
  • Hormone Antagonists (pharmacology)
  • Mammary Neoplasms, Experimental (metabolism, pathology)
  • Mice
  • Mice, Inbred BALB C
  • Mifepristone (pharmacology)
  • Mitosis (drug effects)
  • Neoplasm Transplantation
  • Promoter Regions, Genetic
  • Receptors, Glucocorticoid (metabolism)
  • Receptors, Progesterone (genetics, metabolism)
  • Transplantation, Heterologous
  • Tumor Burden (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: